Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Enanta Pharmaceuticals OCF Yield % Related Terms
Enanta Pharmaceuticals OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:9EP vs PBYI, IPSC, BNTC: OCF Yield % Comparison
For the Biotechnology subindustry, Enanta Pharmaceuticals's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enanta Pharmaceuticals OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Enanta Pharmaceuticals's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enanta Pharmaceuticals (STU:9EP) has a OCF Yield % of -2.06 as of Jul. 16, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Enanta Pharmaceuticals and its competitors. According to the industry distribution chart, Enanta Pharmaceuticals ranks #426 out of 1410 companies in the Biotechnology industry, placing it in the top 30.2%.
Is Enanta Pharmaceuticals' OCF Yield % too high?
Enanta Pharmaceuticals' current OCF Yield % is -2.06. Based on the distribution chart, Enanta Pharmaceuticals ranks #426 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Enanta Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' OCF Yield % compare to PBYI and IPSC?
According to the Biotechnology industry distribution chart, Enanta Pharmaceuticals ranks #426 out of 1410 companies for OCF Yield %. This puts Enanta Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Enanta Pharmaceuticals and its competitors. Enanta Pharmaceuticals's current OCF Yield % is -2.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (STU:9EP) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.57, compared to a current price of €11.50 — trading 51.9% above its estimated fair value. The current OCF Yield % is -2.06. Enanta Pharmaceuticals' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Enanta Pharmaceuticals (STU:9EP), the current OCF Yield % is -2.06 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enanta Pharmaceuticals (STU:9EP) Overvalued in 2026?
Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued.
The current stock price of €11.50 is trading 51.9% above its estimated GF Value™ of €7.57.
GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for STU:9EP:
OCF Yield %: -2.06
GF Value™: €7.57 vs. price of €11.50 (51.9% above fair value)
No single metric tells the full story. See the STU:9EP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
58GF Score
Get the complete analysis for STU:9EP
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:9EP has been successfully added to your 
